RT Journal Article
T1 Assessment of drug-induced liver injury in clinical practice.
A1 Jiménez-Lucena, Isabel
A1 García-Cortés, Miren
A1 Cueto-Galán, Raquel
A1 López-Durán, José Luis
A1 Andrade-Bellido, Raúl Jesús
K1 Hepatotoxicidad
K1 Medicamentos - Toxicidad
AB Currently, pharmaceutical preparations are serious contributors to liver disease, withhepatotoxicity ranking as the most frequent cause for acute liver failure and postmarketingregulatory decisions. The diagnostic approach of drug-induced liver injury(DILI) is still rudimentary and inaccurate because of the lack of reliable markers foruse in general clinical practice. To incriminate any given drug in an episode of liverdysfunction is a step-by-step process that requires a high degree of suspicion,compatible chronology, awareness of the drug’s hepatotoxic potential, the exclusionof alternative causes of liver damage, and the ability to detect the presence of subtledata that favour a toxic aetiology. Clinical and laboratory data may also be assessedwith algorithms or clinical scales, which may add consistency to the clinicaljudgment by translating the suspicion into a quantitative score. The CIOMS/RUCAMinstrument is considered at present the best method for assessing causality in DILI,although it could be improved through the use of large database of bona fide DILIcases for validation criteria.
PB Wiley
SN 0767-3981
YR 2008
FD 2008
LK https://hdl.handle.net/10630/37624
UL https://hdl.handle.net/10630/37624
LA eng
NO Lucena MI, García-Cortés M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008 Apr;22(2):141-58. doi: 10.1111/j.1472-8206.2008.00566.x. Erratum in: Fundam Clin Pharmacol. 2009 Feb;23(1):147. PMID: 18353109.
NO https://openpolicyfinder.jisc.ac.uk/id/publication/13944
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026